Verified against court and regulatory records · No upfront fees · Your information is never sold
Quick Eligibility Review
Answer one question at a time. This usually takes under 2 minutes.
Check your eligibility — free
Answer 2-3 quick questions to review your potential case.
Free · Confidential · About 2 minutes · A case specialist responds within 1 business day
Your answers are never sold or shared without your consent.
Wrongful Death Claims in the Paraquat Litigation
Parkinson’s disease is a progressive neurodegenerative disorder that, while not always listed as the direct cause of death, contributes to mortality through its complications. Aspiration pneumonia (caused by swallowing difficulties), falls resulting in fatal injuries (caused by balance impairment), and cardiovascular complications are common causes of death in Parkinson’s patients. Additionally, the cognitive decline that accompanies advanced Parkinson’s reduces patients’ ability to manage other health conditions, contributing to overall mortality.
Because of the 10–20+ year latency between paraquat exposure and Parkinson’s diagnosis, and the additional years of disease progression before death, many individuals who were exposed to paraquat during the peak use years of the 1980s and 1990s have already died from Parkinson’s-related causes. Their surviving family members retain the right to file wrongful death claims under the laws of most states.
Wrongful death claims are typically brought by the surviving spouse, adult children, or estate of the deceased. The claims seek compensation for the deceased’s pain and suffering during the illness (survival action), medical expenses incurred before death, funeral and burial costs, loss of financial support to the family (particularly significant when the deceased was the primary earner), and loss of companionship, consortium, and parental guidance.
Evidence for Wrongful Death Claims
Wrongful death claims require the same core evidence as living plaintiff claims — documented paraquat exposure and a Parkinson’s disease diagnosis — plus evidence that Parkinson’s disease caused or contributed to the death. Death certificates, autopsy reports (if available), and the deceased’s medical records documenting Parkinson’s as a contributing condition provide this link.
Exposure documentation for deceased plaintiffs may come from employment records, tax returns, agricultural records, testimony from family members and former co-workers, and residential history. Medical records documenting the deceased’s Parkinson’s diagnosis, treatment history, and disease progression are essential. Family members should gather and preserve all available records as soon as possible, as employment and medical records may be more difficult to obtain as time passes.
Research & evidence
Scientific Evidence
Paraquat and Parkinson’s Disease: The Role of Corporate Agnotology
Dorsey ER, et al. (2023). Movement Disorders
Key findings
- Syngenta’s corporate predecessor ICI identified paraquat neurotoxicity in 1958 and confirmed brain penetration in 1966
- The Louise Marks studies documenting substantia nigra cell loss in paraquat-exposed animals were suppressed and not reported to regulators
- Syngenta’s 2003 "Scientific Influencing Strategy" was a coordinated effort to selectively publish favorable research while discrediting independent scientists
- Syngenta specifically targeted Dr. Deborah Cory-Slechta and hired v-Fluence to manage reputation and influence scientific discourse
- The pattern mirrors tobacco industry agnotology documented by Proctor and others, representing a deliberate corporate strategy to maintain a profitable product at the expense of public health
Exposure to Pesticides or Solvents and Risk of Parkinson Disease (Meta-Analysis)
Pezzoli G, Cereda E. (2013). Neurology
Key findings
- Paraquat exposure was associated with an overall odds ratio of 1.64 for Parkinson’s disease, confirming a statistically significant increased risk
- The association was consistent across multiple independent studies conducted in different countries and populations
- Herbicide and pesticide exposure in general was associated with a pooled odds ratio of 1.62 for Parkinson’s disease
- The meta-analytic approach provides the aggregated statistical power that individual studies cannot achieve, strengthening the causal inference
Rotenone, Paraquat, and Parkinson’s Disease (FAME Study)
Tanner CM, Kamel F, Ross GW, et al. (2011). Environmental Health Perspectives
Key findings
- Paraquat users had a 2.5-fold (250%) increased risk of Parkinson’s disease compared to non-users
- The association was statistically significant and persisted after controlling for confounding variables including age, sex, smoking, and other pesticide exposures
- Rotenone use was also associated with increased Parkinson’s risk (2.5x), and both compounds inhibit mitochondrial complex I through similar mechanisms
- The study used objective pesticide application records rather than self-reported exposure, substantially reducing recall bias
FAQ
Frequently Asked Questions
Dive deeper
Related Guides
- Paraquat Aerial Spray DriftAerial application of paraquat produces spray drift that can carry the herbicide hundreds of meters or more from the target area, exposing rural residents, schoolchildren, and bystanders who never directly handled the chemical. Drift exposure is a recognized pathway in the paraquat litigation, and individuals who lived near aerial paraquat operations and developed Parkinson’s disease may have viable claims.
- Paraquat & Early-Onset Parkinson’sEarly-onset Parkinson’s disease (diagnosed before age 50) is more strongly associated with environmental exposures like paraquat than late-onset cases. Individuals who developed Parkinson’s at a younger age after paraquat exposure may have particularly strong claims because early onset is a marker of environmental causation rather than normal aging.
- Paraquat EPA BanDespite more than 70 countries banning paraquat and overwhelming scientific evidence linking it to Parkinson’s disease, the U.S. Environmental Protection Agency has repeatedly declined to ban the herbicide. The EPA’s 2024 registration review reaffirmed paraquat’s approval despite 90 studies submitted by the Michael J. Fox Foundation. This regulatory failure is cited in the litigation as evidence that judicial remedies are necessary to protect American farmworkers and rural communities.
- Paraquat Farmworker ExposureAgricultural workers and farmworkers bear the heaviest burden of paraquat exposure. An estimated 10 million pounds of paraquat are applied annually in the United States, and farmworkers — the majority of whom are Latino — face direct exposure through field work, crop handling, and inadequate protective equipment. The paraquat litigation seeks compensation for farmworkers who developed Parkinson’s disease as a result of occupational exposure.
- Paraquat Parkinson’s Disease LawsuitParaquat exposure causes Parkinson’s disease through a well-characterized mechanism of oxidative stress, mitochondrial dysfunction, and selective dopaminergic neuron death. The FAME study found a 2.5x increased risk, and MDL 3004 encompasses approximately 5,000 cases seeking compensation for individuals diagnosed with Parkinson’s after paraquat exposure.
- Paraquat Settlement AmountsParaquat Parkinson’s settlement amounts are projected to range from $20,000 for early-stage cases to over $1,000,000 for severe, long-duration cases with strong exposure documentation. The MDL framework settlement agreement reached in April 2025 provides the structure for individual case resolution. Average projected settlements are $600,000 to $900,000. Filing now positions your claim for the current settlement distribution cycle.
- Syngenta Paraquat LawsuitSyngenta is the primary defendant in the paraquat Parkinson’s litigation. The company, formed in 2000 from the merger of ICI/Zeneca and Novartis crop sciences, inherited decades of internal research documenting paraquat’s neurotoxicity. Syngenta implemented a "Scientific Influencing Strategy" to suppress and discredit this evidence. Acquired by ChemChina for $43 billion in 2017, Syngenta has paid $187.5 million in initial settlements and agreed to a broader framework settlement in April 2025.
The full investigation